ProCE Banner Activity

Phase II ALTA: Brigatinib Has Promising Activity in Crizotinib-Refractory ALK+ NSCLC

Slideset Download
Conference Coverage
Brigatinib showed a 54% ORR with a median PFS > 1 year in patients with crizotinib-refractory ALK+ NSCLC.

Released: June 13, 2016

Expiration: June 12, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals